Adrastia Biotechnology was founded in 2013 to provide a highly accurate Breast Cancer diagnostic protocol that is easy to administer, non-invasive, will deliver rapid results, and provide women with a personal health history.
Adrastia Biotechnology obtains the urine sample and runs high throughput protein quantification and targeted mRNA/microRNA sequencing to identify a pattern of breast cancer positive or negative as compared to a standard or the woman's own previous pattern. Unlike 100% genomic data, Adrastia's test results are designed to be actionable by the woman's physician and her pattern will be stored in her health record for future reference.
Small (EDWOSB, SB#2001039) Technology Distribution company specializing in innovative products that enable healthcare workforce mobility and healthcare delivery efficiency.
ARIZ is a company dedicated to solving a big problem, cancer. We start at the beginning, the cause of cancer and design drugs that can resolve a specific individual cancer as well as all cancers. ARIZ Precision Medicine uses this methodology to design a specific way to stop the cause of cancer, then target and protect the delivery system and finally, concentrate the drug inside the cancer cell leaving normal cells undamaged.
Our scientists have dedicated a lifetime of research to develop a stable nanocarrier platforms for delivery of therapeutic and diagnostics agens with high potency and high accuracy. Our research is focused on the development of mucoadhesive protein-capsid-based drug delivery systems by drink. Astrid Pharma Corp offers solutions backed by ground-breaking scientific discoveries to make the "needle-free" drug administration dream, a reality.
Cesca Therapeutics is engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine. We focus in three target markets to serve patients, physicians and partners:
Cellular Therapeutics
Medical/Diagnostic Device Development and Commercialization
Cell Manufacturing and Banking
Control. Any Gene. Any Species. Circularis has developed a very powerful and novel method to regulate gene expression and enable increased biotherapeutic production yields up to 10x or more. We can do this for any gene, in any species, with no prior knowledge of the regulatory elements or coding sequence.
We are developing evidence based neurotherapeutics in VR-based video game form. Our treatments target specific cognitive impairments with huge functional implications that impact the lives of the healthy aging, patients with many forms of brain injury and individuals with one of several neurogenetic disorders. Our patent-pending designs combine evidence from clinical cognitive neuroscience with that showing specific improvements of the spatial and temporal information processing systems we target from the "active compound" of playing action video games.
Have you ever had a surgery?
Checking out of the hospital, you were likely you were given a list of products to help you recover.
Easy DME allows clinics to offer all of the products a patient needs to recover, delivered directly to their doorstep.
No more product scavenger hunts.
Easy DME helps clinics to increase revenue while adding a new convenient service to increase patient satisfaction.
Evolve BioSystems will develop and bring to market the next generation of microbiome-based solutions to establish, restore, and maintain a healthy human gut microbiome across a range of unmet clinical needs.
Gates Foundation invests in $40 million venture round by Davis-based company | Sacramento Business Journal, June 13, 2018
Group including Ranadivé invests $20 million in nutrition company | Sacramento Business Journal, May 30, 2017
